Most researchers looking for CJC-1295 in Nāv immediately realize that local retail options are all but absent from local stores. The upside of this online-only market is that serious vendors differentiate entirely through their analytical documentation, giving researchers better verification tools than any physical store could provide. Separating properly characterised CJC-1295 from the rest of the market depends on three things: an HPLC chromatogram documenting ≥98% purity, mass spec data establishing the correct molecular weight, and a batch-specific endotoxin panel. This guide guides Nāv researchers through that evaluation process and explains the signals that distinguish quality CJC-1295 suppliers.
What Studies Say About CJC-1295
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Nāv researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
Where to Buy CJC-1295 — A Researcher's Guide
Quality CJC-1295 sourcing begins with a useful first test: does this vendor share complete COA data without being asked? Suppliers that publish proactively are signalling genuine quality commitment. Mass spectrometry in the COA verifies that the main HPLC peak is actually CJC-1295 and not a structurally similar impurity — HPLC purity alone cannot verify molecular identity. For Nāv researchers evaluating unfamiliar vendors: a test quantity before committing to research volumes before scaling up your order is what experienced peptide researchers consistently do. Keep lyophilised CJC-1295 at freezer temperature (−20°C) until ready to use; reconstitute only the volume needed for upcoming use and return unused portion to the freezer.
Order CJC-1295 — ships to Nāv
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not been through the clinical trial process required for pharmaceutical approval — its safety profile is based on preclinical research and limited human studies. Lyophilised CJC-1295 should be stored frozen (−20°C) immediately upon receipt; repeated freeze-thaw cycles of reconstituted material should be avoided by preparing small aliquots before storage. The most significant preventable safety hazard in CJC-1295 research is endotoxin from inadequately tested product — a verified endotoxin panel in the batch COA is the key safeguard. Researchers using CJC-1295 alongside other research compounds should examine published studies for potential interaction data before running stacked compound experiments.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
